<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="the susceptibility of highly pathogenic avian influenza H5N1 viruses to" exact="oseltamivir" post="using embryonated chicken eggs TareDeeksha S.1KodeSadhana S.1HurtAeron C.3PawarShailesh D.2[1],"/>
 <result pre="OC. Antivirals embryonated chicken eggs H5N1 highly pathogenic avian influenza" exact="oseltamivir" post="The emergence of resistance among highly pathogenic avian influenza"/>
 <result pre="resistance among highly pathogenic avian influenza (HPAI) H5N1 viruses to" exact="oseltamivir" post="has been an increasing cause of concern among public"/>
 <result pre="died3. There are four neuraminidase inhibitor (NAI) antiviral drugs namely," exact="oseltamivir" post="phosphate, zanamivir, laninamivir and peramivir, of which oseltamivir phosphate"/>
 <result pre="drugs namely, oseltamivir phosphate, zanamivir, laninamivir and peramivir, of which" exact="oseltamivir" post="phosphate and zanamivir are the two currently licensed NAI"/>
 <result pre="phosphate, zanamivir, laninamivir and peramivir, of which oseltamivir phosphate and" exact="zanamivir" post="are the two currently licensed NAI drugs used for"/>
 <result pre="NAI drugs used for the treatment and prophylaxis of influenza4;" exact="peramivir" post="is licensed for use in the United States of"/>
 <result pre="the United States of America5. Recently resistance to the NAIs" exact="oseltamivir" post="and zanamivir was reported among H5N1 viruses isolated in"/>
 <result pre="States of America5. Recently resistance to the NAIs oseltamivir and" exact="zanamivir" post="was reported among H5N1 viruses isolated in India6. Due"/>
 <result pre="vivo studies include experiments in mice and ferrets. In ferrets," exact="oseltamivir" post="doses of 5.0 mg/kg twice daily had a significant"/>
 <result pre="reported12. The susceptibility of low pathogenic avian influenza viruses to" exact="oseltamivir" post="carboxylate (OC), the active metabolite of oseltamivir phosphate, has"/>
 <result pre="influenza viruses to oseltamivir carboxylate (OC), the active metabolite of" exact="oseltamivir" post="phosphate, has also been demonstrated13. The advantages of the"/>
 <result pre="A/Perth/265/2009 (pH1N1 H275Y variant) which were sensitive and resistant to" exact="oseltamivir" post="were used as controls. The experiments were carried out"/>
 <result pre="OC in humans after the prescribed 75 mg dose of" exact="oseltamivir" post="phosphate18. In a previous study, 1.75, 3.5, 7, 14,"/>
 <result pre="A/chicken/India/NIV33487/2006 and A/duck/India/TR-NIV4396/2008 with and without treatment with 14 μg/ml" exact="oseltamivir" post="carboxylate, plotted against virus dilutions. Values are mean of"/>
 <result pre="observed. dMean of EID50/ELD50 in the presence of 14 μg/ml" exact="oseltamivir" post="carboxylate, carried out in three replicates each; eMean of"/>
 <result pre="each; eMean of EID50/ELD50 in the absence of 14 μg/ml" exact="oseltamivir" post="carboxylate, carried out in three replicates each; fSince there"/>
 <result pre="a daily dose of 1 to 10 mg per kg" exact="oseltamivir" post="prevented mortality, reduced virus titres in the lungs and"/>
 <result pre="vitro and in vivo studies20. It was shown that after" exact="amantadine" post="addition in cell cultures infected with susceptible HPAI H5N1"/>
 <result pre="there was an absolute reduction in HA titres, whereas the" exact="amantadine" post="resistant viruses, which possessed the molecular signatures required for"/>
 <result pre="seen after treatment with OC for the H5N1 viruses and" exact="oseltamivir" post="sensitive wild-type control reference viruses; whereas, there was no"/>
 <result pre="In the study by Wang et al20, the antiviral drug" exact="ribavirin" post="was administered via the albumen route, while the virus"/>
 <result pre="was inoculated via the allantoic route. It was found that" exact="ribavirin" post="administered in the albumen of the egg is detectable"/>
 <result pre="study, OC which is the active metabolite of the prodrug" exact="oseltamivir" post="phosphate, was administered directly into the allantoic cavity itself"/>
 <result pre="viruses over the last decadeScientifica (Cairo)2014201443062924800107 8HurtACLowtherSMiddletonDBarrIGAssessing the development of" exact="oseltamivir" post="and zanamivir resistance in A(H5N1) influenza viruses using a"/>
 <result pre="the last decadeScientifica (Cairo)2014201443062924800107 8HurtACLowtherSMiddletonDBarrIGAssessing the development of oseltamivir and" exact="zanamivir" post="resistance in A(H5N1) influenza viruses using a ferret modelAntiviral"/>
 <result pre="to study the susceptibility of avian influenza H9N2 viruses to" exact="oseltamivir" post="carboxylateJ Virol Methods2015224677226297959 14collab: World Health OrganizationLaboratory methodologies for"/>
 <result pre="from Australasia and South East Asia to the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivirAntiviral Res200462374515026200 18HaydenGGBruntonLLLazoJSParkerKLAntiviral agents (Non-retroviral)Goodman and Gilman's -"/>
</results>
